Association of Psoriasis with Chronic Kidney Disease and End-stage Renal Disease: a Systematic Review and Meta-analysis
Overview
Affiliations
Background And Objective: Previous studies have shown that patients with psoriasis are at higher risk of developing chronic kidney disease (CKD) and end-stage renal disease (ESRD) compared with general population; however, data on the differences in the occurrence of CKD and ESRD between patients with psoriasis and non-psoriatic controls are limited and inconsistent. The aim of this study was to carry out a comparison of the probability of suffering CKD and ESRD in patients with or without psoriasis by conducting a meta-analysis of cohort studies.
Methods: Cohort studies on PubMed, Web of Science, Embase and Cochrane Library by March, 2023 were searched for. The studies were screened according to pre-established inclusion criteria. Hazard ratios (HRs) and a 95% confidence intervals (CIs) for the renal outcomes among patients with psoriasis were calculated using the random-effect, generic inverse variance method. Subgroup analysis was related to the severity of psoriasis.
Results: A total of seven retrospective cohort studies were included, including 738,104 psoriasis patients and 3,443,438 non-psoriasis subjects, published from 2013 to 2020. Compared to controls without psoriasis, patients with psoriasis had an increased risk of CKD and ESRD, with pooled hazard ratios of 1.65 (95% CI, 1.29-2.12) and 1.37 (95% CI, 1.14-1.64), respectively. Besides, the incidence of CKD and ESRD is positively correlated with the severity of psoriasis.
Conclusion: This study showed that compared to patients without psoriasis, patients with psoriasis, especially those with severe psoriasis, had a significantly increased risk of developing CKD and ESRD. Considering the limitations of this meta-analysis, more high-quality and well-designed studies are needed in the future to validate our findings.
Gau S, Yang C, Li Y, Lee C, Su Y, Chang H Int J Med Sci. 2025; 22(3):558-564.
PMID: 39898256 PMC: 11783075. DOI: 10.7150/ijms.102434.
Diaz-de-la-Cruz E, Hurtado-Nunez G, Sanchez-Ceja S, Torner L, Bartolome-Camacho M, Trujillo-Rangel W Toxicol Rep. 2024; 13:101782.
PMID: 39526234 PMC: 11544083. DOI: 10.1016/j.toxrep.2024.101782.
Chronic kidney disease in patients with psoriatic arthritis: a cohort study.
Kharouf F, Gao S, Al-Matar S, Cook R, Chandran V, Gladman D RMD Open. 2024; 10(4).
PMID: 39510763 PMC: 11552569. DOI: 10.1136/rmdopen-2024-004636.
Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis.
Ridha-Salman H, Shihab E, Hasan H, Abbas A, Khorsheed S, Ayad Fakhri S ACS Pharmacol Transl Sci. 2024; 7(9):2739-2754.
PMID: 39296262 PMC: 11406690. DOI: 10.1021/acsptsci.4c00152.
Oxidative stress and metabolic biomarkers in patients with Psoriasis.
Bakic M, Klisic A, Kocic G, Kocic H, Karanikolic V J Med Biochem. 2024; 43(1):97-105.
PMID: 38496030 PMC: 10944565. DOI: 10.5937/jomb0-45076.